查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813882

美國更年期市場規模、佔有率和趨勢分析報告：按類型、地區和細分市場預測，2025-2033 年

U.S. Menopause Market Size, Share & Trends Analysis Report By Type (Hormonal, Non-Hormonal, and Dietary Supplements), By Country (West, South, Midwest), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國更年期疾病市場規模及趨勢：

美國更年期市場規模預計在 2024 年達到 55.6 億美元，預計到 2033 年將達到 85.8 億美元，2025 年至 2033 年的複合年成長率為 5.0%。

經歷更年期的女性數量不斷增加，人們對更年期以及與更年期相關的症狀的認知和教育不斷提高，這些都推動了對相關產品、服務和治療的需求。根據美國國家醫學圖書館 2023 年的報告，美國每年約有 130 萬名女性經歷更年期，更年期通常發生在 45 至 55 歲之間。此外，人們對天然和有機更年期治療的日益偏好，以及市場上創新產品和技術的出現，例如無荷爾蒙療法和遠端醫療服務，也促進了美國更年期市場的成長。

此外，根據美國婦女健康研究協會的數據，隨著千禧世代的老化，預計美國每天約有6,000名女性將經歷更年期。美國非營利美國AARP於2024年1月進行的一項調查發現，約90%的35歲及以上女性會出現更年期症狀，影響她們的日常生活和工作。世界衛生組織(WHO)的數據表明，閉經通常始於45至56歲之間。然而，一小部分女性（約5%）會在40至45歲之間自然提早閉經。此外，還有一種罕見的疾病，稱為原發性卵巢功能不全，僅有1%的女性會在40歲之前因永久性卵巢衰竭而完全停月經。美國國家醫學圖書館的一項研究表明，某些種族背景的女性比其他地區的女性更容易提前或過早閉經。黑人和西班牙裔女性的閉經發生閉經1.4%，而白人女性僅為 1%。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場譜系
    • 母市場分析
    • 輔助市場分析
  • 美國更年期市場 - 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • COVID-19影響分析
  • 監管和報銷情況
  • 商業環境工具分析：美國更年期市場
    • 波特五力分析
    • PESTLE分析

第4章美國更年期市場：類型評估與趨勢分析

  • 美國更年期市場類型：關鍵要點
  • 美國更年期市場：2024 年和 2033 年類型趨勢和市場佔有率分析
  • 荷爾蒙
  • 非荷爾蒙
  • 營養補充品

第5章美國更年期市場：區域估計與趨勢分析

  • 美國更年期市場（按地區）：關鍵要點
  • 美國更年期市場：2024 年和 2033 年區域趨勢和市場佔有率分析
  • 西
  • 東南
  • 西南
  • 中西部
  • 東北

第6章 競爭態勢

  • 公司分類
  • 企業市場分析
  • 戰略地圖
  • 公司簡介
    • Pfizer Inc.
    • Novo Nordisk A/S
    • TherapeuticsMD
    • Bayer AG
    • AbbVie, Inc.
    • Pure Encapsulations, LLC.
    • PADAGIS LLC
Product Code: GVR-4-68040-310-1

U.S. Menopause Market Size & Trends:

The U.S. menopause market size was estimated at USD 5.56 billion in 2024 and is projected to reach USD 8.58 billion by 2033, growing at a CAGR of 5.0% from 2025 to 2033. The increasing number of women who are reaching menopause age and the rise in awareness and education and its related symptoms are resulting in a growing demand for related products, services, and treatments. According to the report published by the National Library of Medicine in 2023, approximately 1.3 million women experience menopause each year, typically between the age group of 45 to 55 in the U.S. Moreover, the increasing preference for natural and organic menopause remedies and the availability of innovative products and technologies in the market, such as hormone-free therapies and telemedicine services, are also contributing to the growth of the market in the U.S.

In addition, as per the Society for Women's health Research, as the millennial population is aging, the country has around 6,000 women are expected to enter menopause each day in the U.S. A survey conducted by AARP, a U.S.-based nonprofit organization, in January 2024, revealed that approximately 90% of women aged 35 and older experience menopausal symptoms that impact their daily lives and work activities. According to the World Health Organization (WHO), menopause typically begins between the ages of 45 to 56 years. Wherein there is a small proportion of women, approximately 5%, who experience it early, naturally which occurs between the ages of 40 and 45 years old. Furthermore, there is a rare condition known as primary ovarian insufficiency, in which only 1% of women undergo a complete stop of menstruation before the age of 40 due to permanent ovarian failure. Research from the National Library of Medicine indicates that women from certain ethnic backgrounds experience premature and early menopause more frequently than their counterparts from different communities. The incidence of premature menopause is 1.4% for Black and Hispanic women, while it is only 1% for White women.

U.S. Menopause Market Report Segmentation

This report forecasts revenue growth, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 for this study, Grand View Research has segmented the U.S. menopause market report based on type, country.

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hormonal
  • Non-Hormonal
  • Dietary Supplements
  • Country Outlook (Revenue, USD Billion, 2021 - 2033)
  • Southeast
  • West
  • Midwest
  • Southwest
  • Northeast

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
  • 1.6. Data Validation & Publishing
  • 1.7. List of Secondary Sources
  • 1.8. Research Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. U.S. Menopause Market- Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Covid-19 Impact Analysis
  • 3.4. Regulatory & Reimbursement Scenario
  • 3.5. Business Environmental Tools Analysis: U.S. Menopause Market
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTLE Analysis

Chapter 4. U.S. Menopause Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Menopause Market, By Type: Key Takeaways
  • 4.2. U.S. Menopause Market: Type Movement & Market Share Analysis, 2024 & 2033
  • 4.3. Hormonal
    • 4.3.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.4. Non-Hormonal
    • 4.4.1. Non-Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Dietary Supplements
    • 4.5.1. Dietary Supplements Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Menopause Market: Country Estimates & Trend Analysis

  • 5.1. U.S. Menopause Market, By Regional: Key Takeaways
  • 5.2. U.S. Menopause Market: Regional Movement & Market Share Analysis, 2024 & 2033
  • 5.3. West
    • 5.3.1. West Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.4. Southeast
    • 5.4.1. Southeast Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Southwest
    • 5.5.1. Southwest Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Midwest
    • 5.6.1. Midwest Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Northeast
    • 5.7.1. Northeast Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Company Market Position Analysis
  • 6.3. Strategy Mapping
  • 6.4. Company Profiles
    • 6.4.1. Pfizer Inc.
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Novo Nordisk A/S
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. TherapeuticsMD
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Bayer AG
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. AbbVie, Inc.
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Pure Encapsulations, LLC.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. PADAGIS LLC
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. menopause market revenue estimates and forecast, by type, 2021 - 2033 (USD Billion)
  • Table 4 U.S. menopause market revenue estimates and forecast, by regional, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. menopause market: market outlook
  • Fig. 9 U.S. menopause competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. menopause market driver impact
  • Fig. 14 U.S. menopause market restraint impact
  • Fig. 15 U.S. menopause market: Treatment movement analysis
  • Fig. 16 U.S. menopause market: Treatment outlook and key takeaways
  • Fig. 17 Dietary supplements market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 18 OTC pharma products estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 19 Hormonal estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig. 20 Non hormonal market estimates and forecasts, 2021 - 2033 (USD Billion)